Investments of €20,000 or more are made directly in the company. If you are considering such an investment, please contact the CEO of Askel Healthcare Ltd, Virpi Muhonen, at v.muhonen@askelhealthcare.com.

Marketing content

Why invest in Askel Healthcare

Knee joint damage – gateway to osteoarthritis
Cartilage is the smooth tissue that allows joints to move painlessly, but it has very limited capacity to repair itself. When damaged, joints gradually deteriorate, causing pain, stiffness, reduced mobility, and eventually osteoarthritis (OA). Globally, over 242 million people suffer from knee or hip OA(1). and while joint replacement is the standard treatment for advanced disease, there remains a major unmet need for solutions that preserve the natural joint.

Breakthrough solution for a major unmet need – backed by excellent clinical results
The COPLA® Cartilage implant repairs damaged knee joint surfaces in a simple, minimally invasive procedure, restoring pain-free movement and supporting natural cartilage regeneration. Over time, the implant biodegrades safely, leaving only healthy biological tissue. In the ongoing Pilot Trial, 100% of patients have been safely treated with excellent outcomes, confirming COPLA® Cartilage implant’s potential as a game-changing innovation that avoids heavy knee replacement surgery, relieves pain quickly, and supports long-term healing.

Focused path to market approvals with early exit options
Askel Healthcare is advancing toward EU and US market authorisations. This funding round will complete the 20-patient Pilot Trial and prepare for the larger Pivotal Trial of up to 250 patients. While the main goal is full regulatory approval, the strong Pilot Trial results may also trigger interest from strategic partners or acquirers, offering investors an earlier exit option.

Proven capital efficiency & strong track record in non-dilutive funding
Askel Healthcare has reached the clinical stage with just €11 million raised: far less than many invasive MedTech peers. This has been achieved by efficiently combining equity financing with substantial non-dilutive funding such as grants. The company’s disciplined use of capital demonstrates its ability to deliver progress while protecting shareholder value.

Consistent value creation for shareholders
From the very beginning, each funding round has been followed by clear technical and clinical milestones that have consistently increased the company’s valuation. In this funding round current investors can strengthen their position at a reduced-risk stage with near-term value drivers. New investors gain the opportunity to join an advanced-stage MedTech company with a defined regulatory path and multiple upcoming inflection points.

A clear roadmap and strong capability to deliver
Askel Healthcare has a stepwise strategy to secure EU and US marketing approvals. Its lean operations ensure every euro is used to deliver milestones that create value. The company’s core team, supported by an experienced MedTech Board and top-tier partners, enables focused and cost-efficient execution.

1) https://oarsi.org/sites/oarsi/files/library/2018/pdf/oarsi_white_paper_oa_serious_disease121416_1.pdf

Virpi Muhonen, CEO

„Askel Healthcare is on a mission to keep people in motion. Knee pain is a leading cause of disability, keeping millions from the activities they love. Our COPLA® Cartilage implant works with the body’s own biology to repair the knee joint surface – restoring pain-free function and helping prevent further deterioration and osteoarthritis. Our human clinical trial has already delivered excellent results, with patients regaining function fast and sustaining their improvement. With the funding from this round, we will strengthen our clinical proof and take major steps toward market authorisations in the EU and US. We invite you to join us on this journey”

-Virpi Muhonen, CEO


 

Investment information

Days to invest:
21
Investing round ends:
06/10/2025
Type:
Equity offering
Invested so far:
€1,003,833.60
Equity offered:
3.82 – 10.66 %
Price per share:
€9.60
min investment 40 shares
Transaction costs:
1.50 %
Number of existing shares:
2,620,942
Fully diluted shares:
2,960,356
Pre-money valuation:
€25,161,043.20
Maximum issue size:
€3,002,112
Offered units:
312,720
Broker:
Oneplanetcrowd International B.V
License:
ECSPR

Overview

Company profile

Askel Healthcare is a clinical-stage MedTech company focused on addressing the global need for effective knee cartilage repair. Its breakthrough product, the COPLA® Cartilage implant, combines rapid pain relief with long-term joint preservation. Early clinical results have been excellent, positioning the company on a clear path towards regulatory approvals in the EU and US.

The COPLA® Cartilage implant is a class III medical device. Being both implantable and biodegradable, it is regulated under the highest safety and efficacy standards. To obtain market authorisation, the implant will require a CE mark from a Notified Body in the EU and FDA (U.S. Food and Drug Administration) approval in the US. For both the CE mark and FDA approval, the product must be tested and proven superior to the current standard of care in a large clinical study known as the Pivotal Trial.

Knee

Before starting human clinical trials, Askel conducted extensive testing to prove the product’s safety. The company is now in the clinical phase. Its first-in-human Pilot Trial, involving 20 patients across three countries, is ongoing and has shown exceptionally strong initial results. The one-year data demonstrates safety in humans, the benefits of early weight-bearing enabled by the implant, and excellent early functional outcomes. The next major step for the company is to initiate the Pivotal Trial (up to 250 patients) required for market authorisations.

There is a tremendous need for better ways to treat cartilage defects, and the COPLA® Cartilage implant has been developed to meet this need. Osteoarthritis is a major global problem, affecting millions of people worldwide. Approximately one third of the general population has cartilage defects in the knee, although not all cause symptoms. Among athletes, the prevalence is even higher: up to 50%. Untreated knee cartilage defects are well-documented as a risk factor for osteoarthritis, the most common degenerative joint disease globally(1-2). As cartilage damage is known to predispose patients to osteoarthritis, it is critically important to find better solutions for early repair.

Today, surgeons lack effective methods to treat cartilage defects optimally, leaving total joint replacement as the final option: often after patients have endured years of pain and reduced mobility. The COPLA® Cartilage implant was developed together with top-tier orthopaedic surgeons to address this gap and provide a solution for early cartilage repair.

Askel has a proprietary, scalable, in-house manufacturing facility capable for global production of the implant. The process uses Askel’s patented technology and the in-house manufacturing ensures implants of the highest quality. The COPLA® Cartilage implant has been granted Breakthrough Device Designation by the FDA. This designation recognises that the implant provides a more effective treatment for irreversibly debilitating conditions than currently available devices. Through the Breakthrough Devices Program, Askel benefits from ongoing interaction and feedback from FDA experts during the development process, significantly reducing regulatory risk.

Askel’s vision is to become the global standard in surgical cartilage repair. The company’s next steps are to complete its clinical programme, achieve EU and US market authorisations, and partner with leading strategic players to bring the COPLA® Cartilage implant to patients worldwide.

1) Uyen-Sa D., et al. Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis. Ann Intern Med. 2011 Dec 6; 155(11): 725–732.
2) Flanigan D., et al. Prevalence of Chondral Defects in Athletes' Knees: A Systematic Review. Med Sci Sports Exerc. 2010. Oct; 42(10): 1795-801.

Developments since the last funding round with Invesdor

Find out more about what has happened since the last funding round.

Company Info 

Company name: Askel Healthcare Oy
Managing director: Virpi Muhonen
Business ID number: 2818058-4
Founding year: 2017
Address: Naulakatu 3, 33100 Tampere
Industry: Biotech
Locations: Tampere
Website: www.askelhealthcare.com
Social media:

 ​      

Products

Products & business model

The COPLA® Cartilage implant is a medical device designed for knee cartilage repair. It is a biodegradable composite made from natural and synthetic polymers. Due to its biodegradability and implantability in the body, it is classified to the highest risk class (III). 

The cartilage implant is inserted during a simple, minimally invasive surgical procedure to the damaged knee joint surface. Once in place, the implant creates a microenvironment that supports the healing of both cartilage and underlying bone tissue. As healthy joint tissues regenerates, the implant gradually degrades into safe components that are naturally metabolised by the body.

The COPLA® Cartilage implant is designed for dual action:

  • Immediate benefit: The implant fills the damaged area, and its unique properties allow patients to bear full body weight on the operated leg immediately after surgery, promoting rapid pain relief, faster return to normal activities and cartilage formation.
  • Long-term protection: By restoring the biological joint structure, the implant helps prevent further degeneration, reducing the risk of progression to osteoarthritis.

By addressing two major unmet medical needs – rapid restoration of pain-free mobility and prevention of osteoarthritis – the COPLA® Cartilage implant offers both significant clinical impact and strong commercial potential.

Reaching the clinical phase is a major milestone in medical device development, especially for a class III implant. Only a small fraction of early-stage MedTech innovations advance this far, as it requires years of rigorous product development, regulatory preparation, and manufacturing readiness. Achieving market authorisation in both the EU and US demands robust, high-quality clinical evidence generated in human trials to the strictest regulatory standards.

Askel Healthcare’s first human trial is ongoing, and the interim results already demonstrate excellent safety and performance for the COPLA® Cartilage implant. These strong early outcomes significantly reduce the clinical and technical risk for the pivotal trial – the final step in generating the comprehensive evidence package required for regulatory approval.

The company targets EU and US approvals by 2032. Until then, Askel remains pre-revenue, with commercial activities set to begin after regulatory clearance. The strategy is to secure a partnership with a major strategic player for global commercialisation.

Advantages of COPLA® Cartilage implant

Patient recovery is rapid and significant

Pilot Trial results have shown that patients return to pain-free activity within weeks. Patients self-report that their quality of life has improved by more than 120% within six months, and sports activity increased by 120% at one year – demonstrating the ground-breaking potential of the COPLA® Cartilage implant.

Preserving the natural joint – reducing the need for prosthetics

By repairing the damaged joint surface early, the implant can postpone – or even eliminate – the need for knee replacement surgery. The medical and economic benefits of slowing osteoarthritis progression are extensive. A solution that can positively influence the disease trajectory has the potential to transform osteoarthritis treatment and management.

Knee

Treatment designed for broad use

The COPLA® Cartilage implant can be used to treat a wide range of damage, from small to large defects, and is suitable for both younger and older patients, across different activity levels, body weights, and osteoarthritis stages (from none to moderate). The implant is placed in a single, minimally invasive procedure that surgeons can easily adopt with very limited training. Based on Pilot Trial experience, surgeons have consistently praised the simplicity of the operation.

Accessible and scalable

The COPLA® Cartilage implant is a small, easily stored, off-the-shelf product with favourable production economics, ensuring competitive pricing and broad accessibility in global markets.

Knee

Market 

Osteoarthritis is one of the most common joint diseases worldwide and is increasing in prevalence, creating enormous personal and societal costs. The knee joint is the most frequently affected, and the number of people suffering from knee osteoarthritis has more than doubled over the past three decades(1). In the US alone, osteoarthritis leads to an estimated one million knee and hip replacements each year(2). More than half of individuals with symptomatic knee osteoarthritis are under the age of 65(3). Although there is no strict age cutoff, doctors often recommend delayed knee replacement for patients under age 60, when possible, as prosthetic joints typically last only 15 to 20 years and may require revision later.

Osteoarthritis begins with deterioration of the joint surface cartilage and gradually progresses to other joint tissues. Early repair of cartilage damage is critical to slowing down or preventing the disease progression. The COPLA® Cartilage implant was developed precisely for this purpose: to preserve the patient’s own biological joint by repairing cartilage damage early in the disease spectrum and preventing further degeneration.

Market data estimates the total accessible knee cartilage repair market at USD 1–4.5+ billion, with an average annual growth rate of 5%(4-5). Current treatment options are either expensive (up to USD 40,000) or fail to deliver long-term results(6-8). Moreover, they do not address the root cause – osteoarthritis itself.

Askel Healthcare expects to be the first cartilage repair company to not only provide a solution for repairing joint surface damage but also deliver clinical evidence of the positive impact of early cartilage repair on osteoarthritis progression. Clinically and commercially, this would be a game-changer, positioning the COPLA® Cartilage implant not only as the category leader in cartilage repair but also as a breakthrough solution in osteoarthritis management.

1) Cui A., et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. E Clinical Medicine, part of the Lancet Discovery Science, 2020 Dec; 29-30.
2) Barbour KE, et al. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation—United States, 2013–2015. MMWR Morb Mortal Wkly Rep. 2017;66(9):246-253.
3) https://www.arthritis.org/getmedia/e1256607-fa87-4593-aa8a-8db4f291072a/2019-abtn-final-march-2019.pdf  
4) https://www.databridgemarketresearch.com/reports/global-cartilage-repair-market
5) https://www.factmr.com/report/knee-cartilage-repair-market
6) https://medcitynews.com/2018/09/vericel-brings-cell-therapy-to-knee-patients/
7) Kon E., et al. Arthroscopic second-generation autologous chondrocyte implantation compared with microfracture for chondral lesions of the knee: prospective nonrandomized study at 5 years. Am J Sports Med. 2009 Jan;37(1):33-41.
8) Mithoefer K., et al. Clinical Outcome and Return to Competition after Microfracture in the Athlete's Knee: An Evidence-Based Systematic Review. Cartilage. 2010 Apr;1(2):113-20.

Impact

Icon 1

Longer life expectancy and a growing focus on physical health and quality of life drive demand for innovations supporting joints' long-term functionality. Moreover, the strained public healthcare systems drive the need for cost-efficient surgical treatment that supports fast recovery and long-term health benefits. 

Leadership

Askel Healthcare is led by its two co-founders, Dr. Virpi Muhonen and Dr. Anne-Marie Haaparanta, who combine deep scientific expertise with proven capability in advancing innovative medical technologies toward market. Together, they lead a lean, expert-driven organisation supported by a network of top-tier clinical, regulatory, and commercial partners. Moreover, the company is governed by a Board of Directors with strong international, commercial and industry expertise to guide the company toward successful market entry and growth, and a Clinical Advisory Board combined with deep expertise in orthopaedics, especially in cartilage repair.

  

Virpi Muhonen, Chief Executive Officer, Co-founder, Board Member

Dr. Virpi Muhonen

Chief Executive Officer, Co-founder, Board Member

Muhonen holds an MSc in animal physiology and a PhD in orthopaedic cell biology, with research focused on cartilage tissue engineering and regenerative medicine. As a principal investigator at the Orthopaedic Research Laboratory at the University of Helsinki, she led studies on cartilage regeneration and joint health, work that laid the scientific foundation for Askel Healthcare. She has guided the company from its founding in 2017 to the clinical stage: a considerable achievement for an early-stage MedTech, particularly with a class III medical device. She is passionate about translating research into commercial innovations, a mission to which she has devoted much of her free time.

  

Anne-Marie Haaparanta, CTO

Dr. Anne-Marie Haaparanta

Chief Technology Officer, Co-founder, Board Member

Haaparanta has an MSc in biomaterials and a PhD in biomedical engineering. In Askel Healthcare, she is leading the product development, production, and IPR of the company. She has 20 years of experience of biomaterials for medical applications both in academia and industry. Her scientific work and multidisciplinary cooperation led to the invention of COPLA® Cartilage implant. She is a research and technology minded person with high ambition to bring the best tissue engineering approaches from lab to clinical use. After a decade of academic research, she is devoted to bringing Askel Healthcare’s cartilage repair implant to the market, and to the benefit of patients.

  

Ted Bird

Ted Bird

Chairman of the Board

Bird joined the Board of Askel Healthcare in 2023. He has over 40 years of global Commercial, Executive and Board leadership experience in the medical device arena, with deep expertise and an extensive network of surgeons, distributors and industry leaders in orthopaedics and spine surgery. Bird is currently Vice President, North America, at Demetra Spine, Vice President, Spine Commercial, at OsteoRemedies, Strategic Advisor at Orthoson, and Principal at Bird Medical Group, a strategic consulting firm for MedTech startups.

  

Professor Mats Brittberg (MD) Chairman of the Clinical Advisory Board

Professor Mats Brittberg

Chairman of the Clinical Advisory Board

Professor Brittberg is a member of the Cartilage Research Unit at University of Gothenburg and an orthopedic surgeon at Region Halland Orthopaedics (Varberg Hospital). He is a professor of orthopaedics connected to the Institution of clinical sciences and orthopaedic department, University of Gothenburg. He is one of the most recognized global Key Opinion Leaders in cartilage repair. He is the former President and an active member of the International Cartilage Repair and Joint Preservation Society: the number one society of joint health.

Full description of Askel’s Board of Directors can be found here: The Board and Management - Askel Healthcare

Full description of Askel’s Clinical Advisory Board can be found here: Clinical Advisory Board (CAB) - Askel Healthcare

Company structure

Askel Healthcare Oy is a single entity owned directly by its 1,147 shareholders. 

Distribution of the company shares

Askel Healthcare has 1,147 shareholders, most of whom have joined through previous funding rounds with Invesdor. Askel Healthcare has one share series. The five largest shareholders are listed in the table below: 

*The registration of the new 6 800 shares is currently pending at PRH (Finnish Patent and Registration Office), but is showed in the total amount of shares. 

Shareholder

Shares

Votes 
1 Virpi Muhonen 426,474 16.27 %
2 Anne-Marie Haaparanta 425,474 16.23 %
3 Cenitz AH  222,228 8.48 %
4 Biothom Oy 100,996 3.85 %
5 Peter Uppstu 60,000 2.29 %
Other shareholders (1,142) 1,385,770 52.89 %
TOTAL 2,620,942 100 %

Shareholders

Developments at Askel Healthcare since the last funding round with Invesdor

Since the last funding round with Invesdor in 2023, Askel Healthcare has made significant progress across all key areas of its operations.

Clinical development

Since the first patient was operated on in January 2023, the Pilot Trial has progressed successfully. All 20 patients (100%) have reached their 12-month follow-up, with excellent outcomes. The first 8 patients (40%) have now reached the 24-month follow-up, and results continue to be excellent. By that time, the implant has been degraded, leaving only new biological tissue in place. The full 24-month dataset for all 20 patients will be independently reported by the end of 2026. Importantly, the implant’s safety for human use has been confirmed, with no device-related adverse events reported.

The protocol for the Pivotal Trial is already prepared, drafted in collaboration with leading experts in the field. Final adjustments will be made based on the Pilot Trial’s independent report and regulatory agency feedback prior to starting the study.

Production and quality

A wide range of quality assurance and regulatory requirements for both the product and its manufacturing have been fulfilled, meeting the stringent demands of a class III medical device.

Intellectual property

Progress in intellectual property protection has been equally strong. The technology patent has been granted and is effective in 23 countries. In addition, the patent processes remain ongoing in seven other countries. In addition, product patent applications have been filed in Europe, the US, and China, further strengthening the patent portfolio.

Organisation and governance

The Board of Directors has been strengthened with the addition of two US-based industry experts.  Staffing levels have been adjusted to align with future needs, ensuring cost efficiency while maintaining the expertise required to reach upcoming value-inflection milestones. To complement this lean structure, the company has built a comprehensive expert service network that enables timely and flexible execution.

Use of funds

Scenario 1

(€1,000,000 collected in the financing round)

If Askel collects less than €2,500,000 in this financing round, the company will continue to raise additional funds from other sources. With the minimum €1,000,000 Askel can reach the following primary milestones:

  • Finalise the Pilot Trial and obtain the final independent report.
  • Strengthen the intellectual property (IPR) portfolio with new granted patents.
  • Trigger the early exit opportunity by engaging with potential acquirers who have requested immediate follow-up once the report is available – providing a risk-mitigation option if Series A financing is not secured.

Scenario 2

(€2,500,000 or more collected in the financing round)

If Askel raises €2,500,000, it enables the company to reach several primary milestones: 

  • Finalise the Pilot Trial and obtain the final independent report.
  • Finalise the Pivotal Trial design based on Pilot Trial results and regulatory feedback, significantly reducing both clinical and regulatory risks.
  • Build full readiness of product development and production to start the Pivotal Trial, enabling a rapid launch immediately after securing Series A financing.
  • Strengthen the intellectual property (IPR) portfolio with new granted patents.
  • Raise Series A financing to advance through the pivotal clinical trial and achieve both EU and the US market authorisations – the main pathway to maximising long-term value.

With €2,500,000–3,000,000 raised, the additional resources will enable Askel to both strengthen execution of critical milestones and expedite regulatory and operational processes leading to the Pivotal Trial. Stronger financial resources will position Askel more favorably for the upcoming Series A round to secure funding for the Pivotal Trial and market authorisations.

Financial figures & growth

Actual and planned figures

Get an insight into Askel Healthcare's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Login Sign up

Valuation

Icon Money

Askel’s pre-money valuation is €25,161,043.20. The increase from the previous round in June 2023 reflects the company’s significant progress since then. A further uptick in valuation is expected once the final independent report from the Pilot Trial is obtained by the end of 2026.

Askel’s primary goal is to obtain EU and US market authorisations and to exit the company upon achieving these approvals at the latest. The company does not plan to commercialise the COPLA® Cartilage implant independently.

The funding raised in this round will be sufficient to complete the Pilot Trial and strengthen the IPR portfolio. Depending on the total amount raised, it may also be used to build the product development, production, quality, and regulatory readiness needed to start the Pivotal Trial required for market authorisations.

The direct costs of the Pivotal Trial are estimated at approximately €8.5 million, with the total funding need between 2027 and 2032 estimated at €20 million. Askel Healthcare plans to finance the Pivotal Trial and other activities required for regulatory approval through a combination of additional equity financing and extensive use of non-dilutive funding. The company has an outstanding track record in securing such funding, including a prestigious €2.5 million EIC Accelerator grant by European Innovation Council.

As part of the blended EIC Accelerator financing, the company has also received a term sheet from the EIC Fund for an investment of up to €4 million in the Series A.

Askel has raised a total of €11 million to date: a remarkably modest amount for a pre-revenue MedTech company that has already reached the clinical stage. Of this, €4 million has been secured as non-dilutive funding and €7 million as dilutive funding.

In addition, the company has received an indicative term sheet from the EIC Fund (the Venture Capital investment arm of the European Innovation Council) for an equity investment of up to €4 million in the Series A round. The investment is contingent upon securing a qualified new lead investor, with the EIC Fund contributing up to one-third of the total capital raised in the round and matching the lead investor’s commitment. Crowdfunding is not considered as qualified new lead investor.

Askel will continue discussions with potential lead investors, but expects to close the Series A round no earlier than the end of 2026, once the Pilot Trial has concluded and the final independent report has been received.

Year
Type of funding
Amount
Pre-money valuation
Total, €

2017

Equity

Grant

Grant

Equity crowdfunding

€99,995

€50,000

€3,600

€651,191

€1,428,500

N/A

N/A

€2,099,982

€804,786

2018

Debt

Equity

Equity

Grant

€655,000

€99,517

€252,688

€303,750

N/A

€2,761,546

€3,253,188

N/A

€1,310,955


 

2019

 Grant €80,370

N/A

 €80,370

2020

Grant

Equity crowdfunding

Grant

Equity

€10,000

€766,042

€53,624

€508,083

N/A

€5,008,394

N/A

€5,774,435

€1,337,749


 

2021

Grant

Equity

Debt

Grant

€55,900

€1,334,897

€277,214

€2,499,000

N/A

€7,789,535

N/A

N/A

€4,167,011


 

2023

 Equity crowdfunding €2,602,708 €18,339,429 €2,602,708

2024

Equity

Convertible loan

€190,483

€441,820

€24,905,280

N/A

 €632,303

2025

 Equity €65,280 €25,095,763 €65,280

Total

 €11,001,162

Exit scenarios

Askel Healthcare’s primary strategy is to continue development through Pivotal Trial and achieve both EU and US market authorisations: a pathway designed to maximise long-term value. However, strong clinical results, strengthened IP rights and regulatory progress are expected to attract strategic interest earlier, offering investors potential exit opportunities.

The first exit opportunity is expected in late 2026, following completion of the Pilot Trial and receipt of the final independent report. To maximise both the value and likelihood of this exit, part of the proceeds from this round will be used to obtain formal regulatory feedback for the Pivotal Trial design, further strengthening the regulatory pathway and enhancing the company’s attractiveness to strategic acquirers.

Beyond 2026, further exit opportunities could occur at multiple points before market authorisations, with valuation expected to grow as each milestone is reached.

Key value inflection points include:

  • Pilot Trial results and final report
  • Additional intellectual property granted
  • Approval to start the Pivotal Trial
  • Pivotal Trial interim results
  • Market authorisations: CE mark (EU) and FDA approval (US)*

These milestones provide several well-defined points where a strategic acquisition or partnership could occur, allowing investors to capture significant value growth along the way – while keeping the ultimate objective of market authorisation firmly in sight.

*As a benchmark, Smith+Nephew acquired CartiHeal’s Agili-C cartilage repair implant for USD 330 million in 2023, following its FDA approval. At present, Agili-C remains the only FDA-approved medical device for cartilage repair.

Documents

Investment related documents

Log in for more information.

Login Sign up

Updates

Note:

In this update section you will find new, project-relevant information that we receive.

Invesdor does not conduct a separate review of information received after the start of the financing phase.

UPDATE on 15.9.2025

The video features Teemu Paatela (MD, PhD, Director of Orthopaedics and Traumatology & Business Director at Terveystalo, Principal Investigator of the Pilot Trial), presenting the COPLA Pilot Study, highlighting its successful completion and promising results.

UPDATE on 15.9.2025

Askel’s founders, Virpi Muhonen and Anne-Marie Haaparanta, share the story behind starting Askel Healthcare Ltd—and explain why now is the right moment to join them as a shareholder.